#USA #Boston #Ginkgo Bioworks #Tangible Scientific #Inductive Bio

Revolutionizing Drug Discovery: Ginkgo Bioworks, Inductive Bio, and Tangible Scientific Collaboration

In a groundbreaking move for the biopharma industry, Ginkgo Bioworks (NYSE: DNA), a leader in cell programming and biosecurity, has announced a strategic partnership with Inductive Bio and Tangible Scientific. This collaboration aims to democratize access to AI-enhanced lab workflows, revolutionizing drug discovery and optimizing research processes.

The Need for Change in Drug Discovery

The traditional drug discovery model has long been complex and resource-intensive, often involving cumbersome logistics where compounds must be transported across various vendors and locations. These delays hinder the efficient integration of AI-driven design workflows, making it difficult to utilize real-time data in the iterative process of drug development.

Recognizing these challenges, Ginkgo's latest initiative aims to consolidate essential drug discovery processes into a seamless workflow. By integrating their Datapoints offering with the strengths of Inductive Bio's and Tangible Scientific's platforms, they seek to create a more efficient, responsive system that allows researchers to focus on innovation instead of logistical headaches.

Key Features of the Partnership

1. Rapid ADME Profiling by Ginkgo Datapoints: This service provides crucial pharmacokinetic parameters, including absorption, distribution, metabolism, and excretion (ADME) profiling. High-quality readouts will enable quicker decision-making in early-stage drug development.

2. Inductive Bio's Model-Driven Chemistry Platform: This advanced platform utilizes machine learning to predict chemical properties and optimize compound design efficiently. By creating predictive models based on extensive datasets, it allows chemists to focus on high-potential candidates rather than sifting through numerous possibilities.

3. Tangible Scientific's API-Enabled Compound Management: Located near Boston, this facility excels at managing the secure storage and rapid logistics of compounds. Their tech-enabled platform will facilitate seamless integration with Ginkgo Datapoints, allowing scientists to track their compounds in real-time and access important assay results quickly.

The integration of these services represents a significant step towards establishing a cohesive lab-in-the-loop workflow that connects computational modeling, experimental validation, and rapid data delivery into a singular process.

Practical Benefits of Lab-in-the-Loop Workflows

By eliminating silos and fostering collaboration among the three organizations, this partnership aims to enhance the speed and accuracy of drug development efforts. The work will enable:

• - Faster Iterations: AI-driven insights can guide real-time decision-making, allowing scientists to refine their designs swiftly without the delays typically associated with traditional workflows.
• - Cost Reduction: Streamlining logistics and minimizing the need for physical infrastructure investment will help lower the overall expenses linked to drug development.
• - Enhanced Predictive Accuracy: The lab-in-the-loop approach allows for continuous feedback and refinement of predictive models based on experimental outcomes, ultimately improving the quality of leads that move into trials.

John Androsavich, Ginkgo's General Manager of Datapoints, emphasized the importance of evolving drug discovery. He stated, "The image of scientists sketching molecules on a whiteboard is outdated. We're bridging the gap between model-driven design and real-time laboratory results to empower researchers in their quest for new treatments."

Aligning with Regulatory Goals

This innovative approach aligns with regulatory bodies' calls for more efficient drug development timelines, including the FDA's emphasis on accelerated processes and the promotion of AI in biomedical research. Moreover, it echoes a growing trend towards onshoring manufacturing capabilities, fostering a more resilient national infrastructure for drug development.

Conclusion

The partnership between Ginkgo Bioworks, Inductive Bio, and Tangible Scientific is set to redefine drug discovery methodologies in the biopharma sector. By leveraging AI-powered workflows and enhancing collaboration between technology providers, this alliance presents an exciting opportunity for pharmaceutical companies to reduce development times and costs while increasing the success rate of therapeutic designs.

As these services become available, pharmaceutical and biotech teams looking to optimize their research efforts can harness the innovative capabilities of this collaboration, setting the stage for groundbreaking advancements in medicine and treatment options for patients worldwide.